Conventional Oral Systemic Chemotherapy for Postoperative Hepatocellular Carcinoma

• Jian-Hong Zhong

  Hepatobiliary Surgery Department, Tumor Affiliated Hospital of Guangxi Medical University, Nanning 530021, P.R. China

• Le-Qun Li

  Hepatobiliary Surgery Department, Tumor Affiliated Hospital of Guangxi Medical University, Nanning 530021, P.R. China

 Background:The findings of randomized clinical trials (RCTs) about the efficacy of adjuvant conventional oral systemic chemotherapy (COSC) for patients with hepatocellular carcinoma (HCC) after curative hepatic resection (HR) are contradictory. Therefore, a systematic review of clinical trials is needed to evaluate the clinical efficacy of adjuvant COSC.

Methods:Sources such as MEDLINE, EMBASE and the Cochrane Library were systematically searched.All clinical trials comparing curative HR with HR plus COSC for HCC were identified. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated.

Results:Five RCTs and one non-RCT involving a total of 461 patients were included. No treatment-related deaths were reported in the including trials. The adverse effects of COSC were generally mild. However, included studies and meta-analysis showed that adjuvant COSC did not demonstrate statistically significant improvement for the 1-, 3-, and 5-year overall survival. For the 1-, 3-, and 5-year tumor recurrence and recurrence-free survival rates, adjuvant COSC also did not show statistically significant less incidence.

Conclusion:Adjuvant COSC provides no survival benefits for HCC patients after curative HR. Considering the efficacy of sorafenib for advanced HCC and the results of this systematic review, no more trials should be carried out to explore the efficacy of adjuvant COSC.

Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003; 38: 200-207. http://dx.doi.org/10.1016/S0168-8278(02)00360-4

Zhong C, Guo RP, Li JQ, et al. A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma. J Cancer Res Clin Oncol 2009; 135: 1437-1445. http://dx.doi.org/10.1007/s00432-009-0588-2

Capussotti L, Muratore A, Amisano M, et al. Liver resection for hepatocellular carcinoma on cirrhosis: analysis of mortality, morbidity and survival--a European single center experience. Eur J Surg Oncol 2005; 31: 986-993. http://dx.doi.org/10.1016/j.ejso.2005.04.002

Lang H, Sotiropoulos GC, Brokalaki EI, et al. Survival and recurrence rates after resection for hepatocellular carcinoma in noncirrhotic livers. J Am Coll Surg 2007: 205: 27-36. http://dx.doi.org/10.1016/j.jamcollsurg.2007.03.002

Zhong JH, Li H, Li LQ, et al. Adjuvant therapy options following curative treatment of hepatocellular carcinoma: a systematic review of randomized trials. Eur J Surg Oncol 2012; 38: 286-295. http://dx.doi.org/10.1016/j.ejso.2012.01.006

Zhong JH, Li LQ. Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma: A meta-analysis. Hepatol Res 2010; 40: 943-953. http://dx.doi.org/10.1111/j.1872-034X.2010.00710.x

Zhong JH, Ma L, Wu LC, et al. Adoptive immunotherapy for postoperative hepatocellular carcinoma: a systematic review. Int J Clin Pract 2012; 66: 21-27. http://dx.doi.org/10.1111/j.1742-1241.2011.02814.x

Llovet JM, Ruff P, Tassopoulos N, et al. A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. Eur J Cancer 2001; 37: 1352-1358. http://dx.doi.org/10.1016/S0959-8049(01)00100-9

Benson AB 3rd, Mitchell E, Abramson N, et al. Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. Ann Oncol 2002; 13: 576-581. http://dx.doi.org/10.1093/annonc/mdf079

Johnson PJ. Hepatocellular carcinoma: is current therapy really altering outcome? Gut 2002; 51: 459-462. http://dx.doi.org/10.1136/gut.51.4.459

Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. QUOROM Group. Br J Surg 2000; 87: 1448-1454. http://dx.doi.org/10.1046/j.1365-2168.2000.01610.x

Xia Y, Qiu Y, Li J, et al. Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial. Ann Surg Oncol 2010: 17: 3137-3144. http://dx.doi.org/10.1245/s10434-010-1148-3

Hasegawa K, Takayama T, Ijichi M, et al. Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial. Hepatology 2006; 44: 891-895. http://dx.doi.org/10.1002/hep.21341

Yamamoto M, Arii S, Sugahara K, et al. Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma. Br J Surg 1996; 83: 336-340. http://dx.doi.org/10.1002/bjs.1800830313

Kohno H, Nagasue N, Hayashi T, et al. Postoperative adjuvant chemotherapy after radical hepatic resection for hepatocellular carcinoma (HCC). Hepatogastroenterology 1996; 43: 1405-1409.

Ono T, Nagasue N, Kohno H, et al. Adjuvant chemotherapy with epirubicin and carmofur after radical resection of hepatocellular carcinoma: a prospective randomized study. Semin Oncol 1997; 24: S6-18-S16-25.

Takenaka K, Yoshida K, Nishizaki T, et al. Postoperative prophylactic lipiodolization reduces the intrahepatic recurrence of hepatocellular carcinoma. Am J Surg 1995; 169: 400-404. http://dx.doi.org/10.1016/S0002-9610(99)80184-6

Patt YZ, Hassan MM, Aguayo A, et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 2004; 101: 578-586. http://dx.doi.org/10.1002/cncr.20368

Edeline J, Raoul JL, Vauleon E, et al. Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: a retrospective study. World J Gastroenterol 2009; 15: 713-716. http://dx.doi.org/10.3748/wjg.15.713

Zhu AX. Systemic treatment of hepatocellular carcinoma: dawn of a new era? Ann Surg Oncol 2010; 17: 1247-1256. http://dx.doi.org/10.1245/s10434-010-0975-6

Uchino K, Obi S, Tateishi R, et al. Systemic combination therapy of intravenous continuous 5-fluorouracil and subcutaneous pegylated interferon alfa-2a for advanced hepatocellular carcinoma. J Gastroenterol 2012; 47: 1152-1159. http://dx.doi.org/10.1007/s00535-012-0574-3

Cao H, Phan H, Yang LX. Improved chemotherapy for hepatocellular carcinoma. Anticancer Res 2012; 32: 1379-1386.

Ono T, Yamanoi A, Nazmy El Assal O, et al. Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials. Cancer 2001; 91: 2378-2385. http://dx.doi.org/10.1002/1097-0142(20010615)91:12<2378::AID-CNCR1271>3.0.CO;2-2

Yan F, Wang XM, Liu ZC, et al. JNK1, JNK2, and JNK3 are involved in P-glycoprotein-mediated multidrug resistance of hepatocellular carcinoma cells. Hepatobiliary Pancreat Dis Int 2010; 9: 287-295.

Matsushima-Nishiwaki R, Kumada T, Nagasawa T, et al. Direct Association of Heat Shock Protein 20 (HSPB6) with Phosphoinositide 3-kinase (PI3K) in Human Hepatocellular Carcinoma: Regulation of the PI3K Activity. PLoS One 2013; 8: e78440. http://dx.doi.org/10.1371/journal.pone.0078440

Davis AJ, Tannock JF. Repopulation of tumour cells between cycles of chemotherapy: a neglected factor. Lancet Oncol 2000; 1: 86-93. http://dx.doi.org/10.1016/S1470-2045(00)00019-X

Lai EC, Lo CM, Fan ST, et al. Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial. Arch Surg 1998; 133: 183-188. http://dx.doi.org/10.1001/archsurg.133.2.183

Abou-Alfa GK, Johnson P, Knox JJ, et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 2010; 304: 2154-2160. http://dx.doi.org/10.1001/jama.2010.1672

Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390. http://dx.doi.org/10.1056/NEJMoa0708857

Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34. http://dx.doi.org/10.1016/S1470-2045(08)70285-7

• PDF